Divalproex Sodium
Product Images NDC 53808-0831

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 53808-0831). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Divalproex Sodium Extend-release Tablets, Usp 500 mg Bottle Label (Divalpoex Sod 500mg Mylan)

Divalproex Sodium Extend-release Tablets, Usp 500 mg Bottle Label (Divalpoex Sod 500mg Mylan)
FDA Label Image

Divalproex Structural Formula (Fd4949b2 1af2 4725 899f F54cc5cd2db6 01)

Divalproex Structural Formula (Fd4949b2 1af2 4725 899f F54cc5cd2db6 01)
FDA Label Image

Proportion Of Patients Achieving Any Particular Level Of Improvement Was Consistently Higher For Valproate Than For Placebo (Fd4949b2 1af2 4725 899f F54cc5cd2db6 02)

Proportion Of Patients Achieving Any Particular Level Of Improvement Was Consistently Higher For Valproate Than For Placebo (Fd4949b2 1af2 4725 899f F54cc5cd2db6 02)
This document appears to be a graph or chart displaying the percentage reduction in CPS rate between patients who received Divalproex Sodium Delayed-Release and a placebo. The chart displays three categories: Improvement, No Change, and Worsening, and indicates that 50% of patients experienced improvement when treated with Divalproex Sodium Delayed-Release.*
FDA Label Image

Proportion Of Patients Achieving Any Particular Level Of Reduction Was Consistently Higher For High Dose Valproate Than For Low Dose Valproate (Fd4949b2 1af2 4725 899f F54cc5cd2db6 03)

Proportion Of Patients Achieving Any Particular Level Of Reduction Was Consistently Higher For High Dose Valproate Than For Low Dose Valproate (Fd4949b2 1af2 4725 899f F54cc5cd2db6 03)
The text includes a chart with the percentage reduction in CPS rate for different medications, along with a graph showing the percentage of patients who experience improvement, no change or worsening with High and Low Dose Divalproex Sodium Delayed Release medication. No further information is available.*
FDA Label Image

Figure 3 Mean Reduction In 4-week Migraine Headache Rates (Fd4949b2 1af2 4725 899f F54cc5cd2db6 04)

Figure 3 Mean Reduction In 4-week Migraine Headache Rates (Fd4949b2 1af2 4725 899f F54cc5cd2db6 04)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.